# Stephane Bancel CEO of Moderna

- **Show:** In Good Company with Nicolai Tangen
- **Published:** 18 May 2022
- **Source:** https://shows.acast.com/in-good-company-with-nicolai-tangen/episodes/stephane-bancel-ceo-of-moderna
- **Transcript:** https://podcasts.opennash.com/shows/in-good-company-with-nicolai-tangen/stephane-bancel-ceo-of-moderna-3768f3/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

Moderna CEO Stephane Bancel argues that mRNA works as a platform. Because it is an information molecule, one digital, automated process can make any vaccine or drug by changing only the genetic code. That let Moderna go from a published virus sequence to a human trial in about two months. Bancel says the same platform could also serve rare and neglected diseases that traditional drug makers cannot profitably address.

The main tension is speed versus responsibility. Bancel describes working seven days a week for nine months, yet he deliberately slowed the phase three trial to enrol more African-American volunteers. A similar tension runs through his views on money and ethics: he puts patients first, gives away an unprofitable drug, and says the real limit now is talent, not money.

## Key insights

1. **mRNA lets vaccines be designed from data alone** Bancel says Moderna never had the virus in its lab. It designed the vaccine on a computer from the published genetic sequence, and robots then made it using the same manufacturing process every time.
2. **Moderna deliberately slowed its trial for diversity** By mid-August 2020 the phase three trial had too few African-American participants. Moderna closed some sites that were enrolling only white people and opened a new one, to avoid a vaccine that a distrustful community would not take.
3. **The 100-microgram dose choice was a gamble** Moderna had to choose its phase three dose before phase two antibody data was ready. Bancel says it picked 100 micrograms over 50, which he believes gave longer protection than competing vaccines.
4. **Moderna gave away an unprofitable rare-disease drug** Breaking even on a drug for a disease affecting only hundreds of children would have meant charging about $1 million per child per year. Moderna instead handed the intellectual property to a foundation and promised to supply the drug free.
5. **The goal is a yearly combined respiratory booster** Bancel says a lifetime vaccine is not scientifically realistic, but a yearly shot covering COVID, flu, RSV and other coronaviruses is. He argues that the virus's mutations will slow down because the spike protein's genetic code is finite.

## Questions this episode answers

### How did Moderna make a vaccine so quickly after the virus appeared?

Bancel says mRNA is an information molecule, so Moderna designed the vaccine on a computer from the virus's published genetic sequence and robots made it. The manufacturing process stays the same, and only the order of the genetic letters changes, so the first human trial began about two months after the sequence was released.

### Why did Moderna slow down its main clinical trial?

Bancel says the trial was recruiting too few African-American volunteers. Moderna feared that a community with a history of being mistreated in medical studies would not trust the vaccine, so it shut some sites and opened a new one to recruit more.

### What does it mean that mRNA is a platform technology?

Bancel says every Moderna product uses the same four genetic letters and the same factories, so learning carries over from one product to the next. He compares Moderna to Netflix rather than a blockbuster, where each traditional drug is made differently.

### Will people need COVID shots every year?

Bancel expects a yearly booster, adapted to that year's variant and possibly combined with flu and RSV, rather than a lifetime vaccine. He says the virus's mutations should slow because the spike protein's genetic code is finite, but this is his expectation, not a certainty.

### How does Moderna handle drugs that cannot make money?

Bancel says there are about a dozen rare diseases where the price needed to break even would be obscene. He says Moderna would rather do these through partnerships with foundations or governments, as it did by giving a Crigler-Najjar drug to a foundation, and the same approach could cover tropical diseases.

## Facts

- **Stephane Bancel** [0:00:37]: "And there was a Wall Street Journal article that I read when I was actually in the south of France on vacation just a few days after Christmas 2019"
- **Stephane Bancel** [0:01:20]: "So we waited for January 10, when the Chinese put this genetic sequence online."
- **Stephane Bancel** [0:01:45]: "It's only when I'm in Davos the week of January 20 that I realized that this was going to be a pandemic like 1918."
- **Stephane Bancel** [0:02:17]: "we have this technology that we've been working on for 10 years we've done 9 vaccines in human testing when COVID-19 appears"
- **Nicolai Tangen** [0:03:21]: "Now, you went from the first sequence of a virus in January 2020 to a vaccine in phase one clinical trial two months later."
- **Stephane Bancel** [0:03:57]: "We use genetic information, so just data, to design the vaccine on the computer. And then the instructions go to robots, and the robots start making the vaccine."
- **Stephane Bancel** [0:03:57]: "Because the only difference with flu vaccine and COVID vaccine and Zika vaccine is only the orders of the letters on the message."
- **Stephane Bancel** [0:04:27]: "We started around February of 2020 to actually work seven days a week which was dreadful because it was not a few weekends it was for nine months"
- **Stephane Bancel** [0:06:03]: "we started a phase three study in July 26 of 2020."
- **Stephane Bancel** [0:06:55]: "We actually shut down a few of the clinical trial sites where they were enrolling only white people and focusing energy and opening a new site to do more recruiting of African-Americans."
- **Stephane Bancel** [0:08:49]: "We set up our own lab, which we were one of the first companies in Massachusetts to set up our own lab back in the spring of 2020."
- **Stephane Bancel** [0:10:31]: "I will be sometime on TV or on radio saying, hey, we need to hire 500 people in Cambridge or in Norwood where our plant was."
- **Stephane Bancel** [0:11:18]: "If you look at our plant in Massachusetts that has made $600 million last year in 2021, there is no paper in that plant."
- **Stephane Bancel** [0:13:00]: "we had to pick the dose for phase three without the full dose for phase two data."
- **Stephane Bancel** [0:13:54]: "So we ended up picking 100 micrograms, which ended up giving the Mona vaccine a much longer duration of protection than the other vaccines."
- **Stephane Bancel** [0:02:17]: "I was raised by the Jesuits so kind of a serving mindset I've been in life science all my life"
- **Stephane Bancel** [0:15:15]: "We have now actually two foundations that we've started that my wife is running."
- **Stephane Bancel** [0:16:59]: "Now we have now 46 drugs in development, which is a lot."
- **Stephane Bancel** [0:17:46]: "I used to run BioMérieux. It's a French-based diagnostic company. It was built by a family, the family of Marieux."
- **Stephane Bancel** [0:18:42]: "we recently, in the fall, we gave away a drug for rare genetic disease to a foundation."
- **Stephane Bancel** [0:19:17]: "we realized that because the number of kids is so small, if we just want to break even our clinical costs, we will have to charge a family around $1 million per year per kid."
- **Stephane Bancel** [0:20:41]: "And we committed by contract that if the drug is approved, we will every year supply to those couple hundred kids in the planet."
- **Stephane Bancel** [0:21:31]: "If you look at the numbers in Africa, you have more people dying of malaria today than COVID."
- **Stephane Bancel** [0:23:40]: "So our vision is to save millions of lives every year by providing a once a year booster that has COVID in it"
- **Stephane Bancel** [0:24:36]: "The spike protein has 4 ,000 letters in it, genetic letters."
- **Stephane Bancel** [0:25:56]: "There's not a lot of appetite today to get foreign vaccine used in China."

## Transcript

**[0:00:20] Nicolai Tangen:** First of all, Stephane, thank you so much for taking the time. You know, you come highly recommended from the whole world, and we are super excited to share your story with the Norwegian population. Well, thank you so much for the invitation. Stephane, how did you first hear about the pandemic?

**[0:00:37] Stephane Bancel:** So I first heard about a new virus in China between Christmas 2019 and New Year. Actually, through reading the newspaper, I've been in infectious disease for 25 years and I've been part of a couple outbreak like Ebola of course, H1N1 flu out of Mexico if you recall. And so I always keep a close eye on new outbreaks. And there was a Wall Street Journal article that I read when I was actually in the south of France on vacation just a few days after Christmas 2019 that said there were new cases of pneumonia-like disease in Wuhan, China but from new pathogen agents.

**[0:01:20] Stephane Bancel:** And so I emailed the NIH, the team of Dr. Fauci, to ask them, do you know about this new pathogen agent? And they said, no, we're tracking it, but we don't know what it is. A few weeks after, we knew it was coronavirus, but it was not SARS or MERS. It was a new one. So we waited for January 10, when the Chinese put this genetic sequence online. So what did you think then? So we thought it was an outbreak.

**[0:01:45] Stephane Bancel:** At that time, I thought it was going to be an outbreak like SARS or MERS. So we want to develop a vaccine, and we're working on one right away, but to help the outbreak. It's only when I'm in Davos the week of January 20 that I realized that this was going to be a pandemic like 1918. And so I totally moved Moderna from believing it's an outbreak to convince it's a pandemic and make the COVID-19 our number one priority.

**[0:02:10] Nicolai Tangen:** So when you see a situation like that, do you think, geez, this is bad for the world? Or do you think, wow, this is great for Moderna?

**[0:02:17] Stephane Bancel:** No, I think it's awful for the world. I was raised by the Jesuits so kind of a serving mindset I've been in life science all my life and I've been in life science because I want to help people and so when this happened I'm like oh shit it's going to be awful people are going to die by the millions and at the same time we have this technology that we've been working on for 10 years we've done 9 vaccines in human testing when COVID-19 appears and so the first thing is we might be able to help and so we need to get moving because people are going to die by the thousands or millions.

**[0:02:52] Stephane Bancel:** And the other piece too is I get very worried because it's January 2020. I know we cannot get a vaccine in the next few months, but I get very worried for the winter that's coming because like in 1980, again, for all of us that have been in infectious disease, a respiratory virus, and coronavirus is a respiratory virus, is going to be awful in the fall and winter when people are all indoors. And so what I know a lot of people are going to be dying in the spring I think I'm dreading the fall and the winter.

**[0:03:21] Nicolai Tangen:** Now, you went from the first sequence of a virus in January 2020 to a vaccine in phase one clinical trial two months later. I mean, how is that at all possible?

**[0:03:30] Stephane Bancel:** So because of the technology that we have, you know, mRNA, as everybody knows now, is an information molecule. You know, we all have thousands of mRNA in every one of our cells in our body. And we knew the technology could go fast. And we've also invested a lot over the years in IT and robotics to enable the technology to go very fast. And so, you know, in traditional pharmaceuticals, you will need first to have a virus in your lab to work on a vaccine.

**[0:03:57] Stephane Bancel:** Well, in our case, we didn't need a virus. We still, to this day, do not have a virus in our lab. We use genetic information, so just data, to design the vaccine on the computer. And then the instructions go to robots, and the robots start making the vaccine. why is it possible? Because it's always the same manufacturing process, regardless of what we make with the technology. Because the only difference with flu vaccine and COVID vaccine and Zika vaccine is only the orders of the letters on the message.

**[0:04:27] Stephane Bancel:** It's like zero and one for software. Life is made with four letters and all protein in the world, whether it's a plant, a fish, a human, a virus, is using the same four letters to code life information. So how was your life during those two months and what happened in the office? So my life was a bit crazy. We started around February of 2020 to actually work seven days a week which was dreadful because it was not a few weekends it was for nine months where the team worked seven days a week because again we were just so aware that every day mattered to save life.

**[0:05:08] Stephane Bancel:** You know, we were like everybody seeing the trauma happening everywhere with people hospitalized and dying, obviously, but also the lockdowns. The lockdown had a very profound impact on us in terms of what it will do to society, to mental health, to disease, because as you know, a lot of people with cancer, cardiovascular disease and so on, couldn't get to hospital because everybody at the hospital was working night and day saving people, dying from COVID. And also education.

**[0:05:37] Stephane Bancel:** One of the things I worried a lot about was all those kids, especially low-income kids that didn't have a chance to have a computer at home to do remote learning and so on, is what was going to be the impact on their lives if they were going to be

**[0:05:51] Nicolai Tangen:** many quarters losing education. Now, I read somewhere that you slowed down the trials to make them wider and more encompassing. Do you want to explain your thinking behind that?

**[0:06:03] Stephane Bancel:** So we started a phase three study in July 26 of 2020. The first few weeks were fantastic, getting a lot of Americans who volunteered in the study to help us get the data to see if a vaccine was working and was safe. But after a few weeks of great number of people getting the study, we realized that we have a lot of white people. But we are way behind in Latino and we are way, way behind in African-American.

**[0:06:30] Stephane Bancel:** And so we do some actions to try to change the curve and bend the curve. But while we make good progress in Latino, we made not enough progress in African-American. And so we get to a point around mid to the third week of August where it is clear on the current trend, we will have very low African-American representation in the study. And we start to worry a lot about what will it do if a vaccine works?

**[0:06:55] Stephane Bancel:** will we be in a place where African-Americans do not want the vaccine because they don't know if it's safe or not for them and if it's working or not for them. And so after a couple of days of discussion and trying to make things better and so on, we decided with the team to slow down the phase three. We actually shut down a few of the clinical trial sites where they were enrolling only white people and focusing energy and opening a new site to do more recruiting of African-Americans.

**[0:07:25] Nicolai Tangen:** How important was this?

**[0:07:26] Stephane Bancel:** That was really important to us because in the U.S., maybe you guys might not be aware in Norway, but there were some horrible stories of what happened, you know, 56 years ago with clinical studies with African-American that made that that community in the U.S. does not trust the government with their health. They were used literally as human guinea pigs. It was very awful. And so, you know, we said, look, we worked so hard, literally seven days a week for months and months.

**[0:07:58] Stephane Bancel:** If we end up with African-Americans who don't want to take the vaccine because they don't trust it, we will have failed. And so we said, look, we're trying to make this vaccine so that everybody can use it, everybody can feel safe about it. And so we slow down.

**[0:08:17] Nicolai Tangen:** So Stephane, how are you able to scale up your business so quickly? I believe you went from 800 employees in September 19 to more than 3 ,200 people now?

**[0:08:26] Stephane Bancel:** Yes, so that was a very hard part of what we had to do. Plus, we were recruiting people during COVID with lockdowns and people working from home and so on. So what we did is we very quickly identified the problem. As soon as we realized it was going to be a pandemic in January 2020, we said, okay, how do we scale the company? And so we started to increase the size of an HR team to do recruitment.

**[0:08:49] Stephane Bancel:** and we basically industrialized how to hire people. Like in manufacturing, we hired a lot of people to make the vaccine and we had to hire them and train them. And so we had literally an entire section of a building dedicated for interviews where people would come with masks and testing. We set up our own lab, which we were one of the first companies in Massachusetts to set up our own lab back in the spring of 2020.

**[0:09:13] Stephane Bancel:** So people could be tested, be interviewed with masks and they will spend a whole day interviewing. Instead of doing interviews on several weeks, we will just get people on site and have all the Moderna people to interview the candidates in little rooms. And candidates will go room by room. And by the end of the day, we'll decide if we hire that person or not. So it was kind of an industrial effort of how do you hire so many people.

**[0:09:36] Nicolai Tangen:** Is that how you still do it?

**[0:09:37] Stephane Bancel:** Yeah, I mean, we now are back more into a normal way to run the business. But it was just an imperative of how to do it to get the job done.

**[0:09:47] Nicolai Tangen:** And how do you make sure that you get the right people on board with such a speed?

**[0:09:51] Stephane Bancel:** Yeah, so we've developed a lot of tools over the years. Moderna has a pretty distinct culture. We use traditional big pharma that are much slower in how we think about things and much more conservative. This is a place where we try to take calculated risk. Of course, we're not talking about breaking the law or doing things unethical. Those are no go, non-negotiable. but we try to find people who know what they are doing in terms of their skill very very strong and also want to have an impact and you can find such people in big companies sometimes they are frustrated and buried in big companies but if you look carefully you can find those people what was also of

**[0:10:31] Stephane Bancel:** course helping us during the pandemic is the pandemic what do I mean by that Well, Moderna was on national news every day because there was, as you know, every newspaper and TV wanted to know what the vaccine were doing. And as you know, we were early in the race and progressing very quick pace. And so that helped us a lot because as we would advertise that we're hiring a lot of people, you know, I will be sometime on TV or on radio saying, hey, we need to hire 500 people in Cambridge or in Norwood where our plant was.

**[0:11:00] Stephane Bancel:** And so we're trying to get a lot of people wanting to come and help, which also made our job easier.

**[0:11:07] Nicolai Tangen:** I think you were very early on digitizing the whole process. Could you tell us about that? Yes. So having worked at large companies, I have been kind of frustrated over the years.

**[0:11:18] Stephane Bancel:** But how sometimes if you think about a business process that cut across departments, how sometimes it goes digital and then analog on paper and analog and analog and then digital again and analog again. That makes no sense because if you have a digital information, you want and you must keep it digital. And so since the beginning of the company, we embarked on building a fully digital company where all data will be in computers. If you look at our plant in Massachusetts that has made $600 million last year in 2021, there is no paper in that plant.

**[0:11:52] Stephane Bancel:** It's 100 % digital. All the machines are connected to SAP directly into the cloud. And so we try to remove human errors. We try to remove work that is not interesting for employees. As you know, as a species, humans, homo sapiens, we are very bad at doing repetitive tasks. Why? Because we lose interest. We get bored. Humans like doing new things. And so think about all those people that we are in a regulated industry. The way we need to make drugs is very, very clearly defined by the law because we have to protect patient safety, which is, of course, a very, very high priority for us.

**[0:12:32] Stephane Bancel:** But how do you reconcile patient safety and a very regulated way of making drugs and people getting energized by making the drugs if every day they do the same task? And so we try to use machines and computers as much as we can so that our people are doing interesting tasks that motivates them and they want to improve things versus doing the same task every day.

**[0:12:57] Nicolai Tangen:** What were the biggest mistakes you made in this period?

**[0:13:00] Stephane Bancel:** So the biggest mistake I made, a few of them. So one was around people. We hired a lot of people, as you described earlier. I made a few mistakes of people that I was part of the interview process and I supported that ended up not really being a good culture fit with us. So that was unfortunate. The other mistake I made was around the initial dose. You know, we had to pick the dose for phase three without the full dose for phase two data.

**[0:13:31] Stephane Bancel:** We know phase two was safe. If not, we will not have gone to phase three and the regulators, FDA will not have let us go to phase three. But we don't have time to wait for the data of a blood sample of antibody in the blood of a phase two people. So we're hesitating, do we go with 50 micrograms or 100 micrograms? And so this was a very hard decision because nobody knew how much antibody was needed for protecting people.

**[0:13:54] Stephane Bancel:** So we ended up picking 100 micrograms, which ended up giving the Mona vaccine a much longer duration of protection than the other vaccines. But it was a very hard decision because 50 micrograms most probably would have worked, but not has worked as long.

**[0:14:13] Nicolai Tangen:** Changing your tack a bit and just spending some time on you as a person. You mentioned you were raised by Jesuits. Yes. How was that formative for you? So it was really the culture of serving, which was a very profound impact on me.

**[0:14:29] Stephane Bancel:** As I was a teenager, as part of my schooling, not only they give you a good education and so on, but they make you volunteer. And so we spend a lot of time working with homeless people, people who have no job and are unemployed trying to find jobs again and so this spending time i think as a young person realizing that there is a lot of people suffering around and that you can help with your your head and with your hands was very formative in who i became as an elder as i told you all my life i've been in life science because i find it very energizing to work to help over human being and so i really believe

**[0:15:07] Stephane Bancel:** that time with jesuit was very very formative in who i became

**[0:15:10] Nicolai Tangen:** as an adult. Do you think that has changed your view on money as well? Yes, as well. I've never

**[0:15:15] Stephane Bancel:** worked for money. I always worked for my family as enough money to live comfortably, like I think all of us. But money has never been a goal in itself. I'm actually quite fortunate that I have a wonderful wife who now is spending all our time awake to give away the money we made at the company. We have now actually two foundations that we've started that my wife is running. I'm helping a little bit on the strategy side of it.

**[0:15:41] Stephane Bancel:** I don't have a lot of time, as you can imagine, with Moderna. Usually that's how we spend our weekend. Usually the Sunday is really around discussing foundation projects. But it's good when you can use your time to help other people that are suffering. Your life has a lot of meaning.

**[0:15:57] Nicolai Tangen:** Absolutely. And staying on the topic of ethics, what are the most challenging ethical dilemmas that you face as a company? I think there was one that was hard last year was really which country you supply.

**[0:16:13] Stephane Bancel:** We had a lot of issues with being forbidden to export. I spent a lot of time trying to convince government to allow us to export. It was extremely frustrating that politics was in the way of getting people protected. That was really, really frustrating. And we pushed as hard as being threatened by some government. So that was really hard. The one that is hard today, that now the world is in oversupply of vaccine, which is a great thing, we would rather have more vaccines and having to throw out some vaccines than not enough for the planet, obviously, is as we look forward to all the drugs Moderna is working on, which is you always have a limitation.

**[0:16:59] Stephane Bancel:** Today, thankfully, it is not money. It is talent. And so when you have a limitation, is what do you do and what do you not do? And so what is really hard for us today is there's a lot of exciting drugs in cancer or in rare genetic disease that my team is working on. Now we have now 46 drugs in development, which is a lot. I think soon we're going to have 80 or 90 drugs in development.

**[0:17:23] Stephane Bancel:** But that's really the dilemmas we have today is we have a lot of good drug ideas and we cannot take them to a clinic as fast as we wish. And that's really, really heavy burden to carry.

**[0:17:34] Nicolai Tangen:** And in your industry, you always have to balance making money and at the same time making sure that people and countries can afford what you produce. Just how does such a debate look like?

**[0:17:46] Stephane Bancel:** You know, I used to run BioMérieux. It's a French-based diagnostic company. It was built by a family, the family of Marieux. When I was CEO, Monsieur Marieux was the chairman. He was third generation. And one of the things I learned with him is that in life science, if you take care of a patient, money will follow. And so I've always kept that kind of mindset. As we went into the COVID-19 vaccine, we had no idea how much we were going to charge for a vaccine.

**[0:18:14] Stephane Bancel:** Usually you do marketing team doing studies of price and value and reimbursement and all that stuff. We're in a pandemic. We had no time. I was asked a lot initially, how much are you going to charge a vaccine? I said, I have no idea because I have no time to spend with marketing team to figure out the price for a vaccine. And so I think it was this deep belief, which is if you do the right thing for patients, at the end of the day, you'll make enough profit that you'll be able to have a sustainable business.

**[0:18:42] Stephane Bancel:** And I think when you do things the other way around, you do a lot of things that are wrong and drive actually the wrong culture and you hire the wrong people around you. So I think the patient first is always a wise thing to do. It's a very easy compass to have. And the thing we want to do is to try to invent a new way to build a pharmaceutical company. One example we have, to give you a bit of a sense of our values on that topic of price and so on, is we recently, in the fall, we gave away a drug for rare genetic disease to a foundation.

**[0:19:17] Stephane Bancel:** And why did we do that? Because it's a disease called Kregler-Najar. It's a rare disease. There are only hundreds of kids around the world having that disease. It's a disease that M &A technology, we believe, is very adapted to go and treat. There's no treatment for those kids available. And most of those kids will die when they are teenagers because the disease burden is so high that they cannot make it to adulthood. And so we did a back-of-the-envelope calculation and we realized that because the number of kids is so small, if we just want to break even our clinical costs, we will have to charge a family around $1 million per year per kid.

**[0:19:53] Stephane Bancel:** And as we do this back of the envelope with my team, we're like, this is not possible. It's just inhuman to ask a family or government to pay $1 million per year to keep a kid alive. But we are thinking, okay, how do we do this? Because we cannot not do the drug. The technology should really work very well. And so we decide to go 180 degrees the other side. We say, we're going to give it away.

**[0:20:16] Stephane Bancel:** And how do you do that? Well, we partnered with a foundation where we told them, we're giving you all the intellectual property for the drug. Now you are the one owning the drug. But you will get the doctors and the hospital to volunteer with no cost to do a clinical study. Because they will not do that for a company for profit, but they will do that for a foundation. And we told them, we will give you the drug to give a clinical trial to the kids for free.

**[0:20:41] Stephane Bancel:** We'll make it. And we committed by contract that if the drug is approved, we will every year supply to those couple hundred kids in the planet. We'll supply the drug for free.

**[0:20:53] Nicolai Tangen:** Do you think you'll do more of this?

**[0:20:54] Stephane Bancel:** Yes. So there is around a dozen diseases that are like this, where, as we discussed with our board of directors and our team, the math is always the same, which is the price is obscene that you have to charge just to break even. And so we'd rather do it in this kind of private-public partnership that are creative. Another example of what we are doing now in the same domain is for tropical disease. You know, there's a lot of virus that are hurting people in Africa, Latin America, Asia, that nobody cares about in big pharma, like chikungunya, like dengue, yellow fever.

**[0:21:31] Stephane Bancel:** And we are trying to find ways with governments or foundations to make the Moderna technology available so that we can do those products because people are dying. If you look at the numbers in Africa, you have more people dying of malaria today than COVID. And so there's a lot of things that we can do, given our technology is a platform. Because as we discussed initially,

**[0:21:52] Nicolai Tangen:** mRNA is an information molecule. And because you use the same manufacturing process every time,

**[0:21:57] Stephane Bancel:** you can also use the same factories. So you could see a world where we do rare genetic disease with foundations, like I described. We do tropical disease with foundations or governments to get those products out there because they don't cost us money to do. Because I use the same factory. It's more of a question of how do we find partnership to help us kind of share the cost and so on. But we can do a lot of things like this that will help a lot of people that traditional companies cannot do because every drug in the old pharma world, the way you want to think about it is every drug is an analog drug.

**[0:22:34] Stephane Bancel:** It is a different way to make than the previous drug. And so you don't have a platform benefit like we've seen in the tech world. So the analogy I will make to people is think about Moderna more like a Netflix than a blockbuster. Big Pharma is more like a blockbuster world. No, they make a product, every product is different, but there is no learning between product one and product two. And so in our case, it's the same technology.

**[0:22:57] Stephane Bancel:** It's the same four letters, the same four bricks of life we use for every drug.

**[0:23:05] Nicolai Tangen:** So what's the biggest challenge now in the vaccine role globally? It's really, how do we scale the company? I mean, if you think about it today, respiratory disease still is the number one killer in infectious disease.

**[0:23:18] Stephane Bancel:** There's around 10 virus that you and I have had in our lifetime that we believe we had flu. But if you didn't do a PCR test, you and I didn't know what we had. We had a virus that gave flu-like symptom, but not flu necessarily. Sometimes flu, of course, we got.

**[0:23:33] Nicolai Tangen:** But if you think about it, the mRNA technology is very adapted to combine different mRNA molecules in the same virus.

**[0:23:40] Stephane Bancel:** So our vision is to save millions of lives every year by providing a once a year booster that has COVID in it, of course, adapted to a variant of that year, and flu and RSV and other coronaviruses, so that we all get an annual shot at the local pharmacy or doctor, and you don't become sick or hospitalized or worse, dying of respiratory disease. This we can stop.

**[0:24:07] Nicolai Tangen:** Will there ever be a vaccine which will protect you for a longer period of time, you think?

**[0:24:10] Stephane Bancel:** Yes. The thing we should not confuse is the duration of a vaccine is because the virus keeps mutating. The vaccine that's available today in Norway or America or around the world is a vaccine that was developed for a Wuhan virus strain, which is two years ago. And as you know, in the early quarters of this pandemic, the virus has mutated a lot and very quickly. As the virus will evolve, its pace of mutation is going to slow down.

**[0:24:36] Stephane Bancel:** A virus cannot mutate in an infinite number of ways because mutation is based on the size of a genetic spike protein. The spike protein has 4 ,000 letters in it, genetic letters. So there's not an infinite number of possible mutation. It's a finite number. And so because it's a finite number, over time, the number of mutations will slow down. And as we get new vaccine booster, like we're working right now, to have an Omicron-adapted booster for the fall.

**[0:25:06] Stephane Bancel:** So as the virus stabilizes and as we get updated vaccine, we should get back to having at least, I think, nine months protection. So we can all get a vaccine in the fall, get protected through the fall and the winter. As the immunity, like flu, wanes in the summer, we get another one the year after. I think dreaming right now of a vaccine for a lifetime is not in the cards today scientifically, like flu. But I think getting to once a year booster that is adapted, that we can all have a nice fall and winter and kind of forget we live with COVID, like we live with flu and we live with RSV because we have a good vaccine.

**[0:25:43] Stephane Bancel:** I think that world is really ahead of us starting this fall.

**[0:25:46] Nicolai Tangen:** Well, that sounds like good news. Now, in the meantime, what do you think about China's zero COVID policy? Well, I think it's unfortunate because all the tools exist today.

**[0:25:56] Stephane Bancel:** You know, mRNA vaccines are very good protection against infection and more important hospitalization and death. There's not a lot of appetite today to get foreign vaccine used in China. And that's really unfortunate because the COVID-19 zero policy in China, as you know, is forcing a lot of lockdowns. Even Omicron is more and more infectious. The virus evolves to become more and more infectious, not less. That's evolution. That's only one direction. And so I think it's going to be harder and harder with time for China to control the virus without good vaccines.

**[0:26:31] Nicolai Tangen:** Last question. We have a lot of students who admire deeply what you have been doing. What kind of advice do you have for students who want to work in the pharma or biotech industry? I think it's an advice that I think goes to all students. is do what you're really passionate about.

**[0:26:49] Stephane Bancel:** You know, I had friends when I left college or business school who joined the job for a nice title or for more money. And that is stupid. Life is long and you need to do things that you love to be good at it. As I said before, you know, Homo sapiens is a curious animal, literally. We like to learn. We like to do things that have impact. We all have different tastes, which is great for our planet.

**[0:27:13] Stephane Bancel:** We like different things. We get passionate about different things. But choose a job that is an industry you get energized about. When you get up in the morning, you need to be happy and excited. Choose a company where the culture suits you. Not every company is the same. As I tell candidates, some people join Moderna are very happy. Some people join Moderna are not happy because they are not a good culture fit. So find a company that is a good culture fit for you.

**[0:27:38] Stephane Bancel:** But please do not take a job for a nice title. Do not take a job because you make a tiny bit more money than the other job. Think about your life as a career and as a chess game, which is what are the things you need to learn. I think my advice to people is at least until you are 35 years old, your only obsession should be learning, learning, and learning. And if you do that in a good company with good culture that suits you, maybe not your brother or your cousins, but suits you, and you always want to do the right thing for the company and serve the customer, you will do very well.

**[0:28:16] Nicolai Tangen:** Well, I think that's a tremendous place to finish the conversation. Big thanks for your insights and big thanks for what you've done for the world over the last few years.

**[0:28:24] Stephane Bancel:** Well, thank you so much for your kind word. It has been 10 years of hard work for a large team. And what is exciting is there's a lot of work ahead for us for helping people with many more diseases. And we're making sure not to waste any hour.

**[0:28:39] Nicolai Tangen:** Fantastic. thank you so much good luck thank you so much good luck bye bye
